Relmada Therapeutics, Inc. (RLMD)
4.52
+0.45
(+11.06%)
USD |
NASDAQ |
Sep 11, 16:00
4.62
+0.10
(+2.21%)
After-Hours: 20:00
Relmada Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00 |
| June 30, 2019 | 0.0478 |
| March 31, 2019 | 0.0608 |
| December 31, 2018 | 0.0799 |
| September 30, 2018 | -0.3882 |
| June 30, 2018 | -0.5336 |
| March 31, 2018 | -0.6927 |
| December 31, 2017 | 1.926 |
| September 30, 2017 | 0.596 |
| June 30, 2017 | 0.1895 |
| March 31, 2017 | 0.0099 |
| December 31, 2016 | 0.0235 |
| September 30, 2016 | 0.0295 |
| June 30, 2016 | 0.0389 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.0075 |
| September 30, 2015 | 0.0127 |
| June 30, 2015 | 0.0299 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.0083 |
| September 30, 2014 | -0.0072 |
| February 28, 2014 | 0.00 |
| September 30, 2013 | |
| August 31, 2013 | 0.00 |
| May 31, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 219.06M |
| Total Liabilities (Quarterly) | 12.50M |
| Shareholders Equity (Quarterly) | 206.56M |
| Current Ratio | 29.52 |